Global Paclitaxel Market Growth 2019-2024

Paclitaxel is a mitotic inhibitor used in Cancer chemotherapy; Paclitaxel was discovered in 1962 as a result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it "taxol".
In the last several years, global market of Paclitaxel developed rapidly, with an average growth rate of 12.3%. In 2017, global revenue of Paclitaxel is nearly 80 M USD; the actual production is about 2600 Kg.
The classification of Paclitaxel includes Natural Paclitaxel API and Semi-Synthetic Paclitaxel API, and the proportion of Natural Paclitaxel API in 2017 is about 31.3%, and the proportion is decreasing trend from 2012 to 2017.

According to this study, over the next five years the Paclitaxel market will register a 9.0% CAGR in terms of revenue, the global market size will reach US$ 140 million by 2024, from US$ 90 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Paclitaxel business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Paclitaxel market by product type, application, key manufacturers and key regions and countries.

This study considers the Paclitaxel value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Natural Paclitaxel API
Semi-synthetic Paclitaxel API
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Ovarian Cancer
Cervical Cancer
Breast Cancer
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Phyton
ScinoPharm
Novasep
Samyang
Polymed
TAPI (Teva)
Fresenius-kabi
Huiang biopharma
Southpharma
Yunnan Hande
Hainan Yew Pharm
Jiangsu Yew Biotechnology

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Paclitaxel consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Paclitaxel market by identifying its various subsegments.
Focuses on the key global Paclitaxel manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Paclitaxel with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Paclitaxel submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.